- Home
- GPRO vs PLX Comparison
GPRO vs PLX Comparison
Compare GPRO & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRO
- PLX
- Stock Information
- Founded
- GPRO 2004
- PLX 1993
- Country
- GPRO United States
- PLX United States
- Employees
- GPRO N/A
- PLX N/A
- Industry
- GPRO Industrial Machinery/Components
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GPRO Consumer Discretionary
- PLX Health Care
- Exchange
- GPRO Nasdaq
- PLX Nasdaq
- Market Cap
- GPRO 118.4M
- PLX 127.4M
- IPO Year
- GPRO 2014
- PLX 1998
- Fundamental
- Price
- GPRO $1.51
- PLX $1.51
- Analyst Decision
- GPRO Hold
- PLX Strong Buy
- Analyst Count
- GPRO 1
- PLX 1
- Target Price
- GPRO $1.50
- PLX $15.00
- AVG Volume (30 Days)
- GPRO 20.4M
- PLX 1.3M
- Earning Date
- GPRO 08-05-2025
- PLX 08-13-2025
- Dividend Yield
- GPRO N/A
- PLX N/A
- EPS Growth
- GPRO N/A
- PLX N/A
- EPS
- GPRO N/A
- PLX 0.05
- Revenue
- GPRO $780,312,000.00
- PLX $59,764,000.00
- Revenue This Year
- GPRO N/A
- PLX $65.02
- Revenue Next Year
- GPRO $6.79
- PLX $57.34
- P/E Ratio
- GPRO N/A
- PLX $31.35
- Revenue Growth
- GPRO N/A
- PLX 0.18
- 52 Week Low
- GPRO $0.40
- PLX $0.82
- 52 Week High
- GPRO $2.37
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- GPRO 80.77
- PLX 48.91
- Support Level
- GPRO $0.75
- PLX $1.36
- Resistance Level
- GPRO $2.37
- PLX $1.64
- Average True Range (ATR)
- GPRO 0.18
- PLX 0.07
- MACD
- GPRO 0.08
- PLX 0.02
- Stochastic Oscillator
- GPRO 47.43
- PLX 53.57
About GPRO GoPro Inc.
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.